Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25213091 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCYP11B1CYP11B2 | |
| SCHEMBL26185841 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCYP11B1CYP11B2 | |
| SCHEMBL29450098 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCYP11B1CYP11B2 | |
| SCHEMBL30496996 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCYP11B1CYP11B2 | |
| SCHEMBL30496982 | 1.00 | HTR2A (0.41) | HTR2AHTR2CHTR2BCYP11B1CYP11B2 | |
| SCHEMBL22929078 | 0.84 | HTR2A (0.41) | HTR2AHTR2CHTR2BCYP11B1CYP11B2 | |
| SCHEMBL26188534 | 0.83 | CRBN (0.43) | HTR2AHTR2CHTR2BCRBNDDB1 | |
| SCHEMBL23250094 | 0.83 | CRBN (0.50) | HTR2BCRBNDDB1 | |
| SCHEMBL27309802 | 0.83 | CRBN (0.43) | HTR2AHTR2CHTR2BCRBNDDB1 | |
| SCHEMBL27309787 | 0.83 | CRBN (0.43) | HTR2AHTR2CHTR2BCRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085489-A1 | GSPT1-DEGRADING COMPOUNDS, ANTI-CD33 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250092012-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2025-03-20 | — | — | US | disclosed |
| EP-4508044-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12187699-B2 | GSPT1 compounds and methods of use of the novel compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-10-19 | — | — | US | disclosed |
| WO-2023201282-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023201282-A1 | NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-116457344-A | Low molecular weight protein degradation agent and application thereof | 凯普托尔治疗学股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-4188373-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | Captor Therapeutics S.A. (PL) | 2023-06-07 | — | — | EP | disclosed |
| US-9447070-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3061758-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2749559-B1 | 5-substituted isoindoline compounds | CELGENE CORP (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2291365-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-8877780-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2291365-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009145899-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294489-A1 | LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS | MMP2, PSME2, PSME1 | HTR2A 3060/4885HTR2C 3352/4885HTR2B 3144/4885 |
| US-20230331693-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | GSPT1, GSS, GSPT2 | HTR2A 3240/4885HTR2C 3820/4885HTR2B 3358/4885 |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | HTR2A 101/4885HTR2C 21/4885HTR2B 80/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | HTR2A 101/4885HTR2C 21/4885HTR2B 80/4885 |
| US-20250092012-A1 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | GSPT1, GSS, GSPT2 | HTR2A 3240/4885HTR2C 3820/4885HTR2B 3358/4885 |
| US-12187699-B2 | GSPT1 compounds and methods of use of the novel compounds | GSPT1, GSS, GSPT2 | HTR2A 3240/4885HTR2C 3820/4885HTR2B 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.